journal
https://read.qxmd.com/read/38428836/cannabinoids-in-the-treatment-of-selected-mental-illnesses-practical-approach-and-overview-of-the-literature
#1
JOURNAL ARTICLE
Kirsten R Müller-Vahl
Although an increasing number of patients suffering from mental illnesses self-medicate with cannabis , current knowledge about the efficacy and safety of cannabis -based medicine in psychiatry is still extremely limited. So far, no cannabis -based finished product has been approved for the treatment of a mental illness. There is increasing evidence that cannabinoids may improve symptoms in autism spectrum disorder (ASD), Tourette syndrome (TS), anxiety disorders, and post-traumatic stress disorder (PTSD). According to surveys, patients often use cannabinoids to improve mood, sleep, and symptoms of attention deficit/hyperactivity disorder (ADHD)...
March 1, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38387603/unraveling-the-influence-of-age-iq-education-and-negative-symptoms-on-neurocognitive-performance-in-schizophrenia-a-conditional-inference-tree-analysis
#2
JOURNAL ARTICLE
Xenia M Hart, Yasue Mitsukura, Robert R Bies, Hiroyuki Uchida
INTRODUCTION: The complex nature of neurocognitive impairment in schizophrenia has been discussed in light of the mixed effects of antipsychotic drugs, psychotic symptoms, dopamine D2 receptor blockade, and intelligence quotient (IQ). These factors have not been thoroughly examined before. METHODS: This study conducted a comprehensive re-analysis of the CATIE data using machine learning techniques, in particular Conditional Inference Tree (CTREE) analysis, to investigate associations between neurocognitive functions and moderating factors such as estimated trough dopamine D2 receptor blockade with risperidone, olanzapine, or ziprasidone, Positive and Negative Syndrome Scale (PANSS), and baseline IQ in 573 patients with schizophrenia...
February 22, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38354747/the-relevance-of-integrating-cyp2c19-phenoconversion-effects-into-clinical-pharmacogenetics
#3
JOURNAL ARTICLE
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
INTRODUCTION: CYP2D6 and CYP2C19 functional status as defined by genotype is modulated by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there is no data on the effect size of PC for CYP2C19 functional status. The primary aim of this study was to investigate the impact of PC on CYP2C19 functional status. METHODS: Two patient cohorts (total n=316; 44.2±15.4 years) were investigated for the functional enzyme status of CYP2C19 applying two different correction methods (PCBousman , PCHahn&Roll ) as well as serum concentration and metabolite-to-parent ratio of venlafaxine, amitriptyline, mirtazapine, sertraline, escitalopram, risperidone, and quetiapine...
February 14, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38267003/cannabidiol-and-its-potential-evidence-based-psychiatric-benefits-a-critical-review
#4
JOURNAL ARTICLE
Inga Dammann, Cathrin Rohleder, F Markus Leweke
The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in most indications. This review comprises a comprehensive literature search to identify clinical studies on the effects of CBD in psychiatric conditions...
January 24, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38211630/effectiveness-of-medical-cannabis-for-the-treatment-of-depression-a-naturalistic-outpatient-study
#5
JOURNAL ARTICLE
Michael Specka, Udo Bonnet, Lisa Schmidberg, Julian Wichmann, Martin Keller, Christian Scholze, Norbert Scherbaum
BACKGROUND: There is a lack of studies on the course and effectiveness of medical cannabis in the treatment of major depressive disorder (MDD). METHODS: Retrospective longitudinal (18 weeks) study of n=59 outpatients with MDD, treated with medical cannabis via a telemedical platform. Previous treatment with antidepressant medication was required for inclusion into the study. Standardized data collection was carried out at entry and during monthly consultations. Severity of depression was measured on a 0-10 point rating scale...
January 11, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38198809/overview-chronic-pain-and-cannabis-based-medicines
#6
JOURNAL ARTICLE
Matthias Karst
Chronic pain is primarily conceptualized as a disease in its own right when it is associated with emotional distress and functional impairment. Pathophysiologically, dysfunction of the cortico-mesolimbic connectome is of major importance, with overlapping signals in the nociceptive and stress systems. The endocannabinoid system plays an important role in the central processing of nociceptive signals and regulates the central stress response. Clinically, there is moderate evidence that cannabis-based medicines (CBM) can contribute to a significant reduction in pain, especially the associated pain effect, and improvement in physical function and sleep quality in a proportion of patients with chronic pain...
January 10, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38052239/patient-perspectives-on-pharmacotherapy-of-alcohol-dependence
#7
Julian Wellensiek, Michael Specka, Johannes Just, Markus Banger, Udo Bonnet, Norbert Scherbaum
INTRODUCTION: Pharmacotherapy with drugs like naltrexone or acamprosate is a well-evaluated element in the treatment of alcohol dependence (AD). However, in many countries, these medications are rarely administered. The objective of the present study was to identify from patients' perspective factors that prevent the initiation and compliance with pharmacological treatment of AD. METHODS: Patients from inpatient alcohol withdrawal treatment underwent a standardized interview...
December 5, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37995720/augmentation-of-electroconvulsive-therapy-with-oral-caffeine-a-retrospective-analysis-of-40-patients-with-major-depression
#8
JOURNAL ARTICLE
Peter Nyhuis, Dorothea Mücke, Michael Specka, Norbert Scherbaum
OBJECTIVE: Studies have demonstrated the efficacy of injectable caffeine as an augmentation method in electroconvulsive therapy (ECT). This study investigated whether orally administered caffeine increases seizure duration during ECT. METHODS: Medical records of 40 patients treated with a series of ECT were retrospectively analyzed. Patients whose electroencephalogram (EEG) seizure duration had dropped<30 s, or motor seizure duration<15 s were included...
November 23, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37995719/the-effect-of-electroconvulsive-therapy-on-specific-catatonia-symptoms-and-predictors-of-late-response
#9
JOURNAL ARTICLE
Sigrid Breit, Agnes Meyer, Wolfgang Schmitt, Tobias Bracht, Sebastian Walther
INTRODUCTION: Electroconvulsive therapy (ECT) is known to be effective in the treatment of catatonia, reaching response rates of about 80 to 100%. It is indicated in cases of treatment resistance to benzodiazepines and in life-threatening conditions such as malignant catatonia. Beneficial effects on specific symptoms or predictors of response are less clear. The objective of this retrospective study is to examine the ECT effect on specific catatonia symptoms in the acute phase of the illness and to identify predictors of response...
November 23, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37944562/clozapine-induced-stuttering-case-report-and-literature-review
#10
JOURNAL ARTICLE
Fares Jaballah, Amina Aissa, Uta Ouali, Yosra Zgueb, Rabaa Jomli
No abstract text is available yet for this article.
November 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37944561/prevalence-of-covid-19-and-psychotropic-drug-treatment-in-psychiatric-in-patients-in-germany-in-2020-results-from-a-nationwide-pilot-survey
#11
JOURNAL ARTICLE
Juliane K Mueller, Kira F Ahrens, Michael Bauer, Bernhard T Baune, Stefan Borgwardt, Jürgen Deckert, Katharina Domschke, Regina Ellwanger, Andreas Fallgatter, Thomas Frodl, Jürgen Gallinat, René Gottschalk, Hans J Grabe, Alkomiet Hasan, Sabine C Herpertz, Rene Hurlemann, Frank Jessen, Joseph Kambeitz, Tilo Kircher, Johannes Kornhuber, Klaus Lieb, Andreas Meyer-Lindenberg, Rainer Rupprecht, Norbert Scherbaum, Christiane Schlang, Anja Schneider, Georg Schomerus, Andreas Thoma, Stefan Unterecker, Martin Walter, Henrik Walter, Andreas Reif, Christine Reif-Leonhard
INTRODUCTION: In patients with a pre-existing mental disorder, an increased risk for a first manifestation of a psychiatric disorder in COVID-19 patients, a more severe course of COVID-19 and an increased mortality have been described. Conversely, observations of lower COVID-19 incidences in psychiatric in-patients suggested protective effects of psychiatric treatment and/or psychotropic drugs against COVID-19. METHODS: A retrospective multi-center study was conducted in 24 German psychiatric university hospitals...
November 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37884027/medical-cannabis-legalization-no-contribution-to-rising-stimulant-rates-in-the-usa
#12
JOURNAL ARTICLE
Garrett D Alexander, Luke R Cavanah, Jessica L Goldhirsh, Leighton Y Huey, Brian J Piper
INTRODUCTION: There has been a pronounced increase in the use of Schedule II stimulants to treat attention-deficit hyperactivity disorder (ADHD) in the United States over the last two decades. Interestingly, chronic medical cannabis (MC) use can present with cognitive impairments that resemble ADHD symptoms. This study aimed to determine if MC legalization increased prescription stimulant distribution. METHODS: Information on the distribution of methylphenidate, amphetamine, and lisdexamfetamine for 2006 to 2021 was extracted from the Drug Enforcement Administration's comprehensive database and the three-year population-corrected slopes of stimulant distribution before and after MC program implementation were compared...
October 26, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37846462/factors-associated-with-antidepressant-effects-of-ketamine-a-reanalysis-of-double-blind-randomized-placebo-controlled-trial-of-intravenous-ketamine-for-treatment-resistant-depression
#13
Kengo Yonezawa, Hiroyuki Uchida, Taisuke Yatomi, Yohei Ohtani, Kie Nomoto-Takahashi, Shinichiro Nakajima, Masaru Mimura, Hideaki Tani
INTRODUCTION: Predictors of treatment response to intravenous ketamine remain unclear in patients with treatment-resistant depression (TRD); therefore, this study aimed to clarify these predictors using the US National Institutes of Health database of clinical trials. METHODS: Data from a placebo-controlled, double-blind, randomized controlled trial were used to assess the efficacy of intravenous ketamine in adult patients with TRD (NCT01920555). For the analysis, data were used from the participants who had received therapeutic doses of intravenous ketamine (i...
October 16, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37722411/association-of-four-medication-classes-and-non-suicidal-self-injury-in-adolescents-with-affective-disorders-a-retrospective-chart-review
#14
JOURNAL ARTICLE
Vincent Eggart, Matin Mortazavi, Sophie-Kathrin Kirchner, Daniel Keeser, Lisa Brandstetter, Alkomiet Hasan, Elias Wagner
BACKGROUND: Non-suicidal self-injury (NSSI) behaviour is frequently observed in children and adolescents with psychiatric conditions. Affected individuals are regularly treated with psychotropic drugs, although the impact of these agents on NSSI behaviour remains elusive. METHODS: We performed a retrospective chart review from clinical routine data in a large cohort (N=1140) of adolescent inpatients with primary affective and non-affective psychiatric disorders according to ICD-10 (mean age=15...
September 18, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37699529/interpersonal-needs-mental-pain-and-hopelessness-in-psychiatric-inpatients-with-suicidal-ideation
#15
JOURNAL ARTICLE
Isabella Berardelli, Elena Rogante, Salvatore Sarubbi, Maria Anna Trocchia, Ludovica Longhini, Denise Erbuto, Marco Innamorati, Maurizio Pompili
INTRODUCTION: Suicide is a leading cause of death worldwide and models may help the understanding of the phenomenon and ultimately reduce its burden through effective suicide prevention strategies. The Interpersonal Theory of Suicide and Shneidman's Model have tried to describe different unmet needs related to suicidal ideation. The study aims to assess the association between thwarted belongingness, perceived burdensomeness, and suicidal ideation in a sample of psychiatric inpatients and the mediating role of hopelessness and mental pain in this association...
September 12, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37678394/longitudinal-digital-mood-charting-in-bipolar-disorder-experiences-with-chronorecord-over-20-years
#16
JOURNAL ARTICLE
Michael Bauer, Tasha Glenn, Martin Alda, Paul Grof, Rita Bauer, Ulrich W Ebner-Priemer, Stefan Ehrlich, Andrea Pfennig, Maximilian Pilhatsch, Natalie Rasgon, Peter C Whybrow
INTRODUCTION: Longitudinal study is an essential methodology for understanding disease trajectories, treatment effects, symptom changes, and long-term outcomes of affective disorders. Daily self-charting of mood and other illness-related variables is a commonly recommended intervention. With the widespread acceptance of home computers in the early 2000s, automated tools were developed for patient mood charting, such as ChronoRecord, a software validated by patients with bipolar disorder...
September 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37647941/correction-lithium-therapy-in-old-age-recommendations-from-a-delphi-survey
#17
JOURNAL ARTICLE
Julia Christl, Bruno Müller-Oerlinghausen, Michael Bauer, Daniel Kamp, Fabian Fußer, Jens Benninghoff, Rosa A Fehrenbach, Christian Lange-Asschenfeldt, Michael Rapp, Bernd Ibach, Rainer Schaub, Axel Wollmer, Timm Strotmann-Tack, Michael Hüll, Susanne Biermann, Katharina Roscher, Bernd Meissnest, Alexander Menges, Bernd Weigel, Dorothee Maliszewski-Makowka, Christian Mauerer, Martin Schaefer, Beate Joachimsmeier, Sarah Kayser, Lars Christian Rump, Tillmann Supprian
No abstract text is available yet for this article.
August 30, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37643732/challenges-and-ethical-considerations-to-successfully-implement-artificial-intelligence-in-clinical-medicine-and-neuroscience-a-narrative-review
#18
JOURNAL ARTICLE
Scott Monteith, Tasha Glenn, John R Geddes, Eric D Achtyes, Peter C Whybrow, Michael Bauer
This narrative review discusses how the safe and effective use of clinical artificial intelligence (AI) prediction tools requires recognition of the importance of human intelligence. Human intelligence, creativity, situational awareness, and professional knowledge, are required for successful implementation. The implementation of clinical AI prediction tools may change the workflow in medical practice resulting in new challenges and safety implications. Human understanding of how a clinical AI prediction tool performs in routine and exceptional situations is fundamental to successful implementation...
August 29, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37643731/does-lidocaine-shorten-seizure-duration-in-electroconvulsive-therapy
#19
JOURNAL ARTICLE
Jose López-Ilundain, Alejandro Ballesteros Prados, Ángela S Rosero Enriquez, Mónica Enguita-Germán, Estefania Uriarte Rosquil, Jose López Gil, Ana Marmol Fábrega, Estitxu Martinez de Zabarte Moraza, Alex R Maughan, Javier Yoldi-Murillo
BACKGROUND: Electroconvulsive therapy (ECT) is an effective short-term treatment for schizophrenia and depression, amongst other disorders. Lidocaine is typically added to reduce pain from intravenous propofol injection. However, depending on the dose used in the ECT setting, it can shorten seizure duration. The aim of this study was to investigate the effect of lidocaine dose on seizure duration. METHODS: This retrospective, naturalistic cohort study included 169 patients treated with ECT...
August 29, 2023: Pharmacopsychiatry
https://read.qxmd.com/read/37604167/valproic-acid-induced-thrombocytopenia-in-an-elderly-man-with-schizoaffective-disorder-a-case-report
#20
JOURNAL ARTICLE
Yun Tien
No abstract text is available yet for this article.
August 21, 2023: Pharmacopsychiatry
journal
journal
28729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.